Two birds, one stone: Non-canonical therapeutic effects of the PARP inhibitor Talazoparib
{{output}}
In this issue of Cell Chemical Biology, Palve et al. (2022) identified PARP16 as a non-canonical therapeutic target of the PARP1 inhibitor talazoparib, which synergizes with the WEE1 inhibitor adavosertib to enhance its efficacy. The dual targeting of PARP1 an... ...
